知镜 Cognispect · 医学文献与研究工作台

Efficacy of fludrocortisone for symptom relief in patients with autonomic syncope and hypotensive phenotype.

Kenny RA, Rice C, Russo V, Parente E, De Lange FJ, Boel TT, Groppelli A, Deharo JC, Maille B, Fedorowski A, Juszczyk M, Maggi R, Francisco-Pascual J, Rivasi G, Laffi M, Brignole M.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026-11-03 · PMID 42974690

文献摘要

Aim To assess the efficacy of fludrocortisone therapy in patients with autonomic syncope and hypotensive phenotype. Methods and results Multicentre, prospective, non-randomized study. Fludrocortisone therapy was guided by clinician experience and supported by two 24-hour ambulatory blood pressure monitoring (ABPM) assessments-one before treatment start (ABPM 1) and one after drug optimization (ABPM 2). Primary endpoint: reduction of the syncope burden and presyncopal symptoms based on validated semi structured questionnaires. Secondary endpoint: hypotensive episodes on ABPM. In a cohort of 94 patients treated with fludrocortisone (median age 38 [IQR 21-57]) years, 83% females), 16 patients stopped therapy due to side effects, occurring during optimization (#11) or follow-up (#5). A total of 83 patients were analysed. The average 24-hour systolic blood pressure (SBP) increased from 106.3 ± 8.2 mmHg at ABPM 1 to 112.3 ± 9.3 at ABPM 2 (p = 0.0001). The number of daytime SBP drops Conclusion Fludrocortisone therapy was associated with reduced hypotension and the burden of symptoms both in younger and in older patients. Side effects lead to discontinuation of therapy in 17% of cases.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。